MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchBusiness Wire • 11/14/22
MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundBusiness Wire • 08/30/22
Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesBusiness Wire • 08/03/22
MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 07/26/22
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsBusiness Wire • 07/12/22
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 07/07/22
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 06/21/22
MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid ArthritisBusiness Wire • 04/12/22
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 04/05/22
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24Business Wire • 03/24/22
MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanBusiness Wire • 02/23/22
MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy LifespanBusiness Wire • 02/08/22
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating SarcopeniaBusiness Wire • 01/05/22
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast AsiaBusiness Wire • 12/29/21
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 12/16/21
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021Business Wire • 12/01/21
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending LifespanBusiness Wire • 11/23/21
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin AmericaBusiness Wire • 11/18/21
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy LifespanBusiness Wire • 11/16/21
Week 44 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/30/21
MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis FoundationBusiness Wire • 10/26/21
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21Business Wire • 10/19/21
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBDBusiness Wire • 09/22/21
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy LifespanBusiness Wire • 09/13/21
